Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Oncorus
company
About
Oncorus is an immuno-oncology company developing oncolytic viruses to fight cancer.
- 1 - 10
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $57M
- Industries
- Biotechnology,Medical,Therapeutics
- Founded date
- Apr 1, 2015
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Oncorus, Inc. is a lean early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. Oncorus was founded MPM Managing Director Mitch Finer, a well-known biotechnology entrepreneur. Oncorus is a leader in corporate philanthropy, and has taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$136.50M
Oncorus has raised a total of
$136.50M
in funding over 2 rounds. Their latest funding was raised on
Aug 21, 2019 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 21, 2019 | Series B | $79.50M | 2 | — | — | Detail |
| Jul 19, 2016 | Series A | $57M | 3 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
5
Oncorus is funded by 5 investors.
Shinhan Private Equity
and UBS Oncology Impact Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Shinhan Private Equity
|
— | Series B |
|
|
— | Series B |
|
|
— | Series A |
|
|
— | Series A |
|
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
